Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Factory Mutual Insurance Co. dramatically upped its stake in Regeneron Pharmaceuticals by 210.3%, acquiring an additional ...

The disappointing guidance spurred a downgrade at JPMorgan. - Regeneron Pharmaceuticals (REGN) shares slump after Wells Fargo Securities cut the recommendation on Regeneron Pharmaceuticals Inc. to ...

However, analysts from Cantor Fitzgerald, Oppenheimer, and JPMorgan were among those to reiterate their buy-equivalent ratings on Regeneron (NASDAQ:REGN) despite the trial setback. “We do still ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

JPMorgan Reiterates 2025 Net Interest Income Forecast. Wall Street Awaits Any Word on Dimon Succession Plans. The bank says it is â positioned to deliver strong returns' in the face of ...

Regeneron Pharmaceuticals (REGN ... declined as the maker of contact lenses cut its full-year organic growth outlook and JPMorgan downgraded the stock and lowered its price target on concerns about ...